ZNTL
Zentalis Pharmaceuticals Llc
2.60$
-4.5%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
Zentalis Pharmaceuticals Llc (ZNTL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -70 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.0 | -7.0 | -10.0 | -13 | -17 | -22 | -21 | -27 | -37 | -46 | -33 | -37 | -50 | -43 | -33 | -37 | -49 | -79 | -39 | -41 | -52 | -35 | -44 | -40 | -33 | -35 | -27 | -31 | -33 | -70 | -161 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.2 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.8 | |
| 0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 7.7 | 7.2 | 7.9 | 9.7 | 9.9 | 7.7 | 8.5 | 10 | 17 | 10 | 9.6 | 14 | 13 | 14 | 14 | 13 | 13 | 10 | 31 | 6.5 | 6.3 | 4.8 | 3.1 | 3.2 | 6.4 | 18 | |
| -0.2 | 0.0 | -0.1 | – | 0.2 | 7.3 | 7.3 | 8.2 | 9.7 | 9.7 | -42 | 10 | 12 | 22 | 13 | 16 | 21 | 26 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.5 | 3.5 | 2.4 | 1.1 | -1.0 | -2.5 | 6.6 | 4.7 | 2.9 | -1.3 | 13 | 2.4 | -3.3 | 3.0 | 9.6 | 4.0 | -4.0 | -5.2 | 4.8 | 10 | -16 | 14 | -7.3 | -4.5 | 1.8 | -8.3 | -1.2 | -1.4 | -0.7 | 1.0 | -2.3 | |
| 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.4 | 0.8 | 2.7 | 2.2 | 0.5 | 0.3 | 1.7 | 0.2 | 0.2 | 0.3 | 0.1 | 0.2 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | |
| 0.0 | -0.2 | -0.1 | 0.0 | 0.0 | -119 | -138 | -9.7 | 13 | 67 | -141 | 43 | 20 | -142 | 20 | -12 | 42 | 73 | -117 | -42 | 62 | 34 | 48 | 32 | 40 | 30 | 28 | 32 | 30 | 60 | 151 | |
| – | – | – | – | – | – | – | – | – | 0.1 | 166 | 13 | 1.3 | 209 | 0.6 | 50 | 0.4 | 237 | – | – | -0.2 | – | 0.2 | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | -0.4 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.0 | 82 | -0.1 | 13 | 173 | 156 | -0.6 | -0.6 | -0.3 | 167 | 12 | 1.3 | 209 | 0.6 | 50 | 0.4 | 237 | 0.3 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.2 | 0.0 | 0.1 | -4.6 | -1.1 | -1.1 | -6.7 | |
| -9.0 | -7.1 | 72 | -13 | -3.4 | 32 | -2.6 | -38 | -26 | 20 | -8.4 | 19 | -29 | 24 | -13 | 0.5 | -6.8 | 230 | -156 | -83 | 9.6 | -0.6 | 4.3 | -7.4 | 8.0 | -4.3 | 1.5 | -3.1 | -4.1 | -11 | -17 | |
| -9.0 | -7.1 | -10 | -13 | -17 | -22 | -21 | -28 | -38 | -47 | -36 | -39 | -51 | -43 | -35 | -37 | -49 | -80 | -39 | -41 | -52 | -35 | -44 | -40 | -33 | -35 | -27 | -31 | -33 | -70 | -161 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.